Therapy News and Research

RSS

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

Researchers at the UC Davis Comprehensive Cancer Center have shown that the microRNA, miR-124, reduced tumor growth and increased cell death in castration-resistant prostate cancer.

17 Nov 2015

HITLAB selects five finalists for HITLAB World Cup

HITLAB has selected five finalists for its HITLAB World Cup, an international competition that promotes original solutions to pressing healthcare challenges. The best and brightest in healthcare innovation, the finalists, will present their ideas at the HITLAB Innovators SummitSM on December 4, 2015, at Columbia University's Alfred Lerner Hall.

17 Nov 2015

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment.

17 Nov 2015

Archbishop of York agrees to become Antibiotic Research UK's Patron

Antibiotic Research UK, a charity founded in 2014 to save modern medicine from the onslaught of superbugs, is delighted to announce that the Most Reverend & Right Honourable Dr John Sentamu, Archbishop of York has agreed to become the Charity’s Patron.

17 Nov 2015

Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Nearly 50 percent of Medicaid patients infected with chronic hepatitis C whose doctors had prescribed newer, life-saving antiviral drugs were denied coverage to the therapies because they weren't considered "a medical necessity" or because the patients tested positive for alcohol/drugs, among other reasons, according to new Penn Medicine research.

17 Nov 2015

Study reveals why colorectal cancer still returns in some patients after treatment

Cetuximab, marketed as Erbitux, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival.

17 Nov 2015

Researchers identify new target for novel immune-oncology treatments

By studying a type of immune cells, a team of researchers at the IRCM led by André Veillette, MD, identified the mechanism of action for a new target for novel immune-oncology treatments. Their discovery is published today in the print edition of the scientific journal the Journal of Experimental Medicine.

17 Nov 2015

Drug prevents onset of cognitive and cellular effects in mouse model of Alzheimer’s disease

In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain's stress circuitry significantly reduces Alzheimer's disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition.

17 Nov 2015

IASLC commends FDA's decision to grant accelerated approval for new lung cancer therapy

The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.

17 Nov 2015

Health care costs for Alzheimer's disease patients increase a year before diagnosis

The health care costs of patients diagnosed with Alzheimer's disease (AD) start to increase already one year before the diagnosis, shows a new study from the University of Eastern Finland.

17 Nov 2015

Improved gene therapy treatment shows promise in mice with cystic fibrosis

An improved gene therapy treatment can cure mice with cystic fibrosis (CF). Cell cultures from CF patients, too, respond well to the treatment. Those are the encouraging results of a study presented by the Laboratory for Molecular Virology and Gene Therapy at KU Leuven, Belgium.

17 Nov 2015

Escalation therapy for neuromyelitis attacks improves remission rates

Researchers recommend escalating patients’ therapy in the event of continuing attacks of neuromyelitis optica, basing sequential treatment on the type of attack and prior treatment response.

16 Nov 2015

Treating insomnia through a CBT device? An interview with Dr Ebrahim

Insomnia refers to a clinical condition that is characterised by one or more of the following – difficulty initiating sleep and/or maintaining sleep and/or waking up too early AND associated with symptoms the next day such as sleepiness, lethargy, loss of concentration.

16 Nov 2015

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA.

15 Nov 2015

Adynovate approved for patients with Hemophilia A

The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Adynovate is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding.

15 Nov 2015

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

14 Nov 2015

Pathophysiological biomarkers predict PAH prognosis

Researchers have identified three biomarkers that signify an increased risk of death or requirement for lung transplantation in patients with pulmonary arterial hypertension.

13 Nov 2015

DePuy offers ambulatory surgery outpatient solutions for joint replacement patients

DePuy Synthes Companies announces the national launch of the DEPUY SYNTHES ADVANTAGE™ Outpatient Solutions Program to facilitate best practices and protocols for joint replacement in ambulatory surgical centers (ASCs) and outpatient hospitals throughout the United States.

13 Nov 2015

Therapy News and Research

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

HITLAB selects five finalists for HITLAB World Cup

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Archbishop of York agrees to become Antibiotic Research UK's Patron

Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Study reveals why colorectal cancer still returns in some patients after treatment

Researchers identify new target for novel immune-oncology treatments

Drug prevents onset of cognitive and cellular effects in mouse model of Alzheimer’s disease

IASLC commends FDA's decision to grant accelerated approval for new lung cancer therapy

Health care costs for Alzheimer's disease patients increase a year before diagnosis

Improved gene therapy treatment shows promise in mice with cystic fibrosis

Escalation therapy for neuromyelitis attacks improves remission rates

Treating insomnia through a CBT device? An interview with Dr Ebrahim

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Adynovate approved for patients with Hemophilia A

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

Pathophysiological biomarkers predict PAH prognosis

DePuy offers ambulatory surgery outpatient solutions for joint replacement patients

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News